|
AU2013273659A1
|
|
Creatine-ligand compounds and methods of use thereof
|
|
AU2013248196A1
|
|
Methods of treating a neurological disorder with creatine monohydrate
|
|
WO2013003465A2
|
|
Methods and compositions for treating skin
|
|
WO2009002913A1
|
|
Use of creatine compounds to treat dermatitis
|
|
WO2008137137A1
|
|
Creatine ascorbyl derivatives and methods of use thereof
|
|
WO2008124151A2
|
|
Use of creatine compounds for the treatment of eye disorders
|
|
AU2007332800A1
|
|
Creatine compositions for skin treatment
|
|
AU2007249847A1
|
|
Methods of treating a neurological disorder with creatine monohydrate
|
|
EP2023718A2
|
|
Creatine-ligand compounds and methods of use thereof
|
|
AU2006202505A1
|
|
Compositions containing a combination of a creatine compound and a second agent
|
|
AU2006200893A1
|
|
Use of creatine or creatine compounds for skin preservation
|
|
AU2003238872A1
|
|
Methods of treating cognitive dysfunction by modulating brain energy metabolism
|
|
AU5636300A
|
|
Use of creatine or creatine analogs for the prevention and treatment of transmissible spongiform encephalopathies
|
|
AU5761600A
|
|
Use of creatine or creatine compounds for skin preservation
|
|
AU4550999A
|
|
Use of molecules that modulate an energy related associated state
|
|
EP1065931A1
|
|
Compositions containing a combination of a creatine compound and a second agent
|
|
US5998457A
|
|
Creatine analogues for treatment of obesity
|
|
WO9713507A1
|
|
Use of creatine analogues for the treatment of disorders of glucose metabolism
|
|
CA2507753A1
|
|
Use of creatine or creatine analogs for the treatment of diseases of the nervous system
|
|
EP2327404A1
|
|
Use of creatine or creatine analogs for the treatment of diseases of the nervous system
|
